These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35994263)

  • 1. Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era.
    Schaubel DE; Tran AH; Abt PL; Potluri VS; Goldberg DS; Reese PP
    JAMA; 2022 Sep; 328(11):1102-1104. PubMed ID: 35994263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.
    La Hoz RM; Sandıkçı B; Ariyamuthu VK; Tanriover B
    Am J Transplant; 2019 Nov; 19(11):3058-3070. PubMed ID: 31207073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience.
    Molnar MZ; Nair S; Cseprekal O; Yazawa M; Talwar M; Balaraman V; Podila PSB; Mas V; Maluf D; Helmick RA; Campos L; Nezakatgoo N; Eymard C; Horton P; Verma R; Jenkins AH; Handley CR; Snyder HS; Cummings C; Agbim UA; Maliakkal B; Satapathy SK; Eason JD
    Am J Transplant; 2019 Nov; 19(11):3046-3057. PubMed ID: 31306549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of kidney transplantation from HCV-viremic donors into HCV-negative recipients.
    Daloul R; Pesavento TE; Goldberg DS; Reese PP
    Kidney Int; 2021 Dec; 100(6):1190-1198. PubMed ID: 34237327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
    Cannon RM; Locke JE; Orandi BJ; Anderson DJ; Davis EG; Mackelaite L; Dave H; Eng M; Jones CM
    Transplantation; 2020 Jun; 104(6):1215-1228. PubMed ID: 31517783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes.
    Molnar MZ; Azhar A; Tsujita M; Talwar M; Balaraman V; Bhalla A; Podila PSB; Kothadia J; Agbim UA; Maliakkal B; Satapathy SK; Kovesdy CP; Nair S; Eason JD
    Am J Kidney Dis; 2021 May; 77(5):739-747.e1. PubMed ID: 33333148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing increased risk for disease transmission (IRD) kidneys for pediatric renal transplant recipients.
    Hwang CS; Gattineni J; MacConmara M
    Pediatr Nephrol; 2019 Oct; 34(10):1743-1751. PubMed ID: 31243535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-Positive Recipients in the Direct-Acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
    Goldfarb DA
    J Urol; 2020 Dec; 204(6):1369. PubMed ID: 32955983
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives?
    Trotter PB; Summers DM; Ushiro-Lumb I; Robb M; Bradley JA; Powell J; Watson CJE; Neuberger J
    Transplantation; 2018 Apr; 102(4):664-672. PubMed ID: 29166338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
    Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
    Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus and kidney transplantation: Recent trends and paradigm shifts.
    El Helou G; Jay C; Nunez M
    Transplant Rev (Orlando); 2022 Jan; 36(1):100677. PubMed ID: 35063799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful heart-kidney transplantation from a Hepatitis C viremic donor to negative recipient: One year of follow-up.
    Wettersten N; Tran H; Mekeel K; Pretorius V; Adler E; Aslam S
    Transpl Infect Dis; 2019 Feb; 21(1):e13002. PubMed ID: 30222242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
    Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
    Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
    Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
    J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P
    J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy.
    Gupta G; Zhang Y; Carroll NV; Sterling RK
    Am J Transplant; 2018 Oct; 18(10):2496-2505. PubMed ID: 30075489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Donors With Hepatitis C Viremia to Recipients Without Hepatitis C Viremia: A Small Uncontrolled Trial.
    Desai NM; Leung SG; Motter JD; Segev DL; Warren D; Durand CM
    Ann Intern Med; 2023 Dec; 176(12):1682-1684. PubMed ID: 38011702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.